BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at two upcoming healthcare conferences: the Jefferies Healthcare Conference on June 8, 2022, at 9:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 15, 2022, at 12:00 p.m. ET. Investors can access live audio webcasts and replays of these events via the Investors & Media section of BioCryst's website. The company specializes in developing oral small-molecule medicines for rare diseases, with drugs like ORLADEYO® approved in multiple regions, and several ongoing development programs including BCX9930 and galidesivir.

RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022, at 9:00 a.m. ET and the JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 15, 2022, at 12:00 p.m. ET.

Links to a live audio webcast and replay of these presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com 

FAQ

When will BioCryst Pharmaceuticals present at the Jefferies Healthcare Conference?

BioCryst Pharmaceuticals will present at the Jefferies Healthcare Conference on June 8, 2022, at 9:00 a.m. ET.

What date will BioCryst Pharmaceuticals present at the JMP Securities Life Sciences Conference?

BioCryst Pharmaceuticals will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 12:00 p.m. ET.

How can I access the webcasts for BioCryst Pharmaceuticals' presentations?

Live audio webcasts and replays of BioCryst Pharmaceuticals' presentations can be accessed in the Investors & Media section of their website.

What is BioCryst Pharmaceuticals' focus in drug development?

BioCryst Pharmaceuticals focuses on discovering novel oral small-molecule medicines for rare diseases with significant unmet medical needs.

What notable drug does BioCryst Pharmaceuticals have approved?

BioCryst Pharmaceuticals has ORLADEYO® (berotralstat) approved in the U.S., EU, Japan, and other regions.